Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-142 single-dose respiratory safety in obstructive sleep apnea hypopnea
jRCT2031200373Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) comparing TS-142 10 mg with Placebo (2 arms). Primary endpoint: Apnea hypopnea index. Started Feb 2021; status: completed.
02
Drugs
vornorexant
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on jRCT2031200373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200373.